发明名称 Prostate cancer therapy using an engineered respiratory syncytial virus
摘要 The present invention is within the field of oncolytic virotherapy. Oncolytic virotherapy is a strategy using viruses, naturally occurring or genetically modified, to selectively target and destroy tumor cells while leaving surrounding non-malignant cells unharmed Here, an engineered respiratory syncytial virus (RSV), with the NS1 gene deleted (NS1 gene-deficient RSV, ΔNS1 RSV), kills prostate cancer cells, but does not affect normal human cells.
申请公布号 US9060974(B1) 申请公布日期 2015.06.23
申请号 US201113134326 申请日期 2011.06.06
申请人 发明人 Zhang Weidong;Jiang Lixian;Cao Calvin
分类号 A01N63/00;A61K39/155 主分类号 A01N63/00
代理机构 代理人
主权项 1. A method to treat prostate cancer in a patient in need thereof by delivering directly to the cancer an oncolytic engineered respiratory syncytial virus (RSV) with the NS1 gene deleted, wherein the RSV infects and causes oncolysis to thereby treat the patient.
地址